PGCM
DNA icon

Prescott Group Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Prescott Group Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Hold
541,845
– – 0.33% 80
2025
Q4 		$4.5M Buy
+541,845
New +$5.83M 0.42% 66
2025
Q3 		– Sell
-775,568
Closed -$8.73M – 242
2025
Q2 		$8.73M Buy
775,568
+409,851
+112% +$3.18M 1.03% 17
2025
Q1 		$2.08M Buy
365,717
+3,967
+1% +$40.4K 0.3% 104
2024
Q4 		$3.55M Buy
361,750
+90,000
+33% +$771K 0.48% 64
2024
Q3 		$2.21M Buy
+271,750
New +$2.72M 0.32% 100
2023
Q1 		– Sell
-25,825
Closed -$1.75M – 175
2022
Q4 		$1.75M Buy
+25,825
New +$2.38M 0.38% 66

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return